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Abstract
Background: Autoimmune thyroid disease is a common complication of patients with chronic hepatitis C
undergoing combination pegylated interferon-a and ribavirin treatment. A small proportion develops interferon-
induced thyroiditis of which the long term natural history is unknown and how it compares with de novo
thyroiditis. The aim of the study is to determine the natural history of thyroid disease including antibody profile in
this particular setting 36 months from the completion of therapy.
Methods: A cohort of 18 hepatitis C patients (mean age 45 ± 8 years (standard deviation)) who developed
exclusively thyroiditis in this setting was followed every 12 months after the completion of therapy for 36 months.
Investigations included thyrotropin, free tetra-iodothyronine, free tri-iodothyronine levels and thyroid
autoantibodies.
Results: None of the patients developed any long term thyroid disease. Two patients had a prolonged
hypothyroid phase of the thyroiditis early after the completion of treatment but recovered fully. The remaining 16
patients remained euthyroid. Similarly, thyroid autoantibodies all declined and returned to reference range.
Conclusions: The long term natural history in this small series of interferon induced thyroiditis was benign. If a
larger series confirms a similar outcome then there is no long term residual effect on thyroid function and follow-
up testing would not be warranted.
Background
Hepatitis C remains one of the major causes of chronic
liver infection and cirrhosis worldwide. The most effec-
tive and established treatment available for this condi-
tion is the combination ribavirin and pegylated
interferon-a (IFN-a). A major and common adverse
effect of this treatment is the development of thyroid
disease during therapy. A large spectrum of autoim-
mune thyroid disease (TD) has been described to occur
ranging from Graves’ disease to thyroiditis to frank pri-
mary hypothyroidism [1-3]. As the number of patients
undertaking treatment is expected to rise, a proportion
of these patients will progress to develop thyroid
disease. It is therefore important to understand and fully
clarify the natural progression of the disease. This forms
a critical part of the long term management and coun-
selling for these patients. It has been reported that
~50% of these patients recover from this complication
[4,5]. Furthermore, other reports are retrospective and
follow patients in an ad hoc fashion with very variable
and unstandardised duration. In addition, some of the
studied groups included the use of IFN as monotherapy
and regular IFN (rather than pegylated) in combination
with ribavirin [6]. In some cases, patients remain perma-
nently thyroxine dependent although no withdrawal
trials were attempted. The long term natural history of
this condition beyond this time frame remains largely
unknown and it is uncertain whether it is different from
other forms of thyroiditides arising de novo.
The aim of this report is to follow prospectively the
long term natural history of TD 36 months after the
completion of treatment in a cohort of patients who
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interferon and also to compare the outcome with the
natural history of the thyroiditides arising de novo.
Methods
Patients
The patients are all recruited from a Hepatitis C service
centre in a major tertiary referral hospital. A total of 18
patients were available for study. These were retrieved
from a pool of 358 patients over a 5 year period, giving an
annual incidence of ~5.0%. All were followed-up over a
36-month period. All were medication naive, i.e. all were
undergoing therapy for the first time. All other causes of
chronic hepatitis were excluded including hepatitis B and
chronic alcoholic liver disease. Baseline characteristics of
all studied subjects are summarised in Table 1.
Thyroid function assessments
All patients were assessed by an endocrinology team and
confirmed to have thyroiditis whilst receiving interferon
therapy as previously reported [7]. At the end of inter-
feron treatment, all had baseline thyroid function studies
and thyroid autoantibodies, at 12, 24 and 36 months
post therapy. Follow-ups at 24 and 36 months were per-
formed by mail correspondence and telephone inter-
views. Patients were recalled and reviewed formally if
clinically indicated.
Laboratory assay characteristics
Third generation serum TSH, serum fT4 and fT3 were
determined by two-site sandwich immunoassay using an
automated chemiluminescent system (Diagnostic Pro-
ducts Corporation, Immulite 2000). The reference range
(RR) for TSH was 0.4-4.0 mU/L, fT4 10.0-26.0 and fT3
3.5-5.5 pmol/L. The coefficients of variation (CV) were
5.0% and 5.1% at TSH concentrations of 4.0 mU/L and
10.0 mU/L respectively. For fT4, the CV was 6.5% at
10.0 pmol/L and fT3 8.9% at 3.5 pmol/L.
Serum autoantibodies to thyroglobulin and thyroper-
oxidase were measured by agglutination (Serodia-ATG
and Serodia-AMC, Fujirebio, Inc., Tokyo, Japan). Titres
of less than 1:40 were considered normal for both.
Thyroid Stimulating Immunoglobulin was measured
using cell culture and radio-immunoassay. This is an in-
house bioassay using Chinese Hamster Ovary (CHO)
cells in culture to detect the presence of thyroid stimu-
lating activity. The CHO cells are transfected with the
TSH receptor genes and thus are responsive to TSI.
Thyroid-stimulating activity is measured by evaluating
the intracellular release of cAMP induced by the
patient’s serum immunoglobulin on the CHO cells. The
results are reported as units/mL (U/mL). TSI should be
absent in the normal population. A TSI level of <10 is
considered negative, 10-50 as weakly, 50-100 as moder-
ately and >100 U/mL as strongly positive.
Table 1 Baseline characteristics, hepatitic outcomes and thyrotropin outcome profiles in all 18 thyroiditis patients
Subject
No.
Gender Age Hepatitis C
Genotype
Duration of Therapy
(weeks)
SVR End of Rx
TSH
TSH at 12
months
TSH at 24
months
TSH at 36
months
1 M 26 1a 48 Y 2.1 1.8 2.8 3.4
2 M 51 2 24 Y 1.7 3.2 3.1 2.7
3 M 54 3 24 Y 3.8 2.3 2.2 3.2
4 M 49 4 48 Y 1.1 1.4 2.1 2.3
5* F 42 2 24 Y 1.6 1.8 2.1 1.9
6* F 34 3 24 Y 2.4 2.7 2.1 2.0
7 F 49 4 48 Y 3.1 2.9 2.7 2.2
8* F 49 1 48 Y 0.03 1.5 1.2 1.3
9 F 50 2 24 Y 2.2 2.1 2.4 2.5
10* F 37 4 48 Y 6.5 4.5 5.2 2.3
11 F 43 4 48 Y 1.8 1.9 2.3 2.1
12 F 42 3 24 Y 2.1 2.3 1.7 2.5
13* F 43 1 48 N 10.5 2.3 1.8 2.4
14* F 51 3 24 Y 8.8 4.0 3.8 2.3
15 M 57 1 48 N 2.2 2.7 1.9 1.2
16 F 38 3 24 Y 1.9 2.2 2.3 3.7
17 M 57 1 48 Y 4.5 2.5 3.6 2.8
18 F 37 3 24 Y 3.4 3.3 2.5 2.8
*; Cases 5 and 6 required short-term thyroxine supplement, case 8 progressed to develop post-interferon Graves’ like thyrotoxicosis, cases 10 and 14 had
subclinical hypothyroidism and case 13 was in the hypothyroid phase at the end of treatment. SVR; Sustained virologic response, Rx; Treatment, TSH; Thyrotropin.
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Duration of follow-ups started from the completion of
interferon treatment, be it 24 or 48 weeks.
Definition of thyroiditis
Thyroiditis is defined as the triad of clinical and/or bio-
chemical thyrotoxicosis followed by a hypothyroid
phase, with an initial reduced/negligible thyroid pertech-
netate uptake scan. All uptake scans were reviewed by a
specialist nuclear physician consultant. Thyroid autoan-
tibodies may be present but are not considered essential
to the diagnosis.
Results
There were 18 cases of thyroiditis available for the
study. All recovered from their TD at the end of the
study. Cases 5 and 6 required short-term thyroxine
supplement but subsequently were successfully with-
drawn from thyroxine. Case 8 progressed to developed
temporary Graves-like thyrotoxicosis demonstrating the
uncommon tri-phasic thyroiditis that had previously
been reported [8,9]. In addition, cases 10 and 14 had
subclinical hypothyroidism which resolved with time
and did not require thyroxine at any stage, Table 2.
Similarly, case 13 was in the hypothyroid phase of the
thyroiditis at the end of treatment, was treated expec-
tantly and resolved without thyroxine. At 36 months, all
cases had normal thyrotropin levels and all thyroid
autoantibodies were undetectable. No patient required
thyroxine at the end of the study.
With the exception of case 8, thyroid autoantibody
titres declined towards normal at the end of treatment
and remained unaltered throughout the duration of fol-
low-up.
Discussion
This is the first report to prospectively investigate the
natural history of patients who develop thyroiditis dur-
ing treatment with pegylated interferon-a and ribavirin
for chronic hepatitis C infection. It is reassuring to
ascertain that this form of TD is benign and that there
is no long term recurrence or hypothyroidism. This
benign prognosis is encouraging for both patients and
clinicians. There appears to be little need to monitor for
associated thyroid condition beyond 36 months after
completion of treatment.
This benign outcome also parallels the thyroid autoan-
tibodies which similarly resolved. With the exceptions of
one patient (case 8), all thyroid antibodies normalise. In
this affected case, autoantibodies persisted at the end of
treatment suggesting ongoing immunomodulation but
the consequent mild Graves’ disease resolved after 12
months.
The involution of thyroid disease after interferon
exposure is as expected and is probably due to two rea-
sons. Firstly, it is because of the pharmacokinetics of the
Table 2 Auto-antibody profiles in 18 thyroiditis patients
Subject
No.
End of
Rx anti-
TPO
Anti-TPO
at 12
months
Anti-TPO
at 24
months
Anti-TPO
at 36
months
End of
Rx anti-
Tg
Anti-Tg at
12
months
Anti-Tg at
24
months
Anti-Tg at
36
months
End of
Rx TSI
TSI at
12
months
TSI at
24
months
TSI at
36
months
1 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
2 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
3 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
4 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
5* 1024 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
6* 256 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
7 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
8* 16 <1 <1 <1 <1 <1 <1 <1 19 10 <10 <10
9 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
10* <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
11 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
12 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
13* <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
14* 16 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
15 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
16 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
17 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
18 <1 <1 <1 <1 <1 <1 <1 <1 <10 <10 <10 <10
*; see Table 1 legend. Anti-TPO; anti-thyroperoxidase antibody, Anti-Tgl; anti-thyroglobulin antibody, TSI; Thyrotropin stimulating immunoglobulins.
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weeks. As a result, most of the TDs that occur post-
therapy tend to do so in this time frame [10]. Secondly,
once beyond the 6 month period where sustained viro-
logic response (SVR) had been attained, the immunomo-
dulating effect of the hepatitis C viral particle has been
removed and hence its influence on thyroid tissues is no
longer pertinent [11].
However our findings are inconsistent with other retro-
spective reports. Carella et al [12] studied a group of 114
chronic hepatitis C patients after an average of 6.2 years
of follow-up and found some persistence of thyroid auto-
antibodies after 6.2 years of follow-up but without clinical
findings of TDs. However, the s ep a t i e n t sw e r et r e a t e d
with IFN-a alone for 12 months. However the treatment
was monotherapy with regular IFN. Vezali et al [13]
described 2 cases which developed thyroiditis within 1
month of treatment completion and another 3 cases at 6,
6.5 and 26 months respectively. No further details were
forthcoming. The frequency of thyroid testings was not
mentioned during this post-treatment period. Jamil et al
[6] looked at 45 cases of thyroid disease over a 12 year
period but did not comment on the long-term outcomes
of thyroid diseased patients nor the frequency of thyroid
monitoring. Generally speaking in other retrospective
series, the thyroid follow-ups are often ad hoc as a result
and the outcome is not uniform and inconsistent [14,6].
The thyroid surveillance frequency is also inadequate to
assess for the thyroid condition.
Most series report hypothyroidism as the commonest
thyroid disorder in this setting but our experience has
been that of thyroiditis almost exclusively [7]. In this
setting, the prevalence of permanent hypothyroidism has
been reported at ~50% [13] but where attempts or trials
of thyroxine withdrawal were done, none of our patients
required long term supplements. This suggests that the
thyroid has completely recovered from the interferon-
elicited injury and that hypothyroidism occurring in this
setting deserved a trial of withdrawal before being com-
mitted to life-long therapy and all its potential
complications.
The presence of high thyroid autoantibody titres also
heavily influences the involution of thyroid diseases.
Where they persisted or evolved, clinical diseases appear
to follow as evident in cases 5, 6 and 8. However,
because of the sporadic nature of post-treatment thyroid
diseases, it remains uncertain whether routine thyroid
autoantibodies should be performed routinely in this
setting.
The major limitation of this study is the small number
of subjects due the low prevalence of the condition. The
second concern is the testing frequency of 12 month
intervals during which it is conceivable that thyroid
function may have fluctuated during this time.
Regardless, it appears that thyroid disease sustained dur-
ing interferon therapy for chronic hepatitis C infection
is self-limiting and without any long last consequences.
All cases recovered, compared with de novo thyroiditis
where the progression to hypothyroidism can be as high
as 20% in both adults and children [15,16]. Although
there is no data beyond 3 years, it can safely be assumed
that any development of thyroid conditions beyond this
time should be deemed unrelated and treated each on
its own merit. Perhaps monitoring for thyroid disease
could be safely ceased at 6 months follow-up, coinciding
with the SVR review.
Conclusion
Despite the small number, the long term outcome of
interferon induced thyroiditis appears benign. There is
no long term risk of hypothyroidism. Larger studies will
be needed to confirm this outcome. If this is the case,
perhaps there is little need to follow these patients
longer than 6 months after the completion of interferon
therapy. This is to cover for any immediate thyroid con-
ditions that may occur during this time frame. Follow-
ups beyond 3 years appear unwarranted although this
time frame is completely arbitrary.
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